Northwest Biotherapeutics
1996
FOUNDED
PUBLIC
STATUS
11-20
EMPLOYEES
NWBO
STOCK SYMBOL
1
INVESTMENTS
$0.27
SHARE PRICE
(As of Friday Closing)
Description
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 4800 Montgomery Lane
- Suite 800
- Bethesda, MD 20814
- United States
+1 (240) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Northwest Biotherapeutics’s full profile, request a free trial.
Northwest Biotherapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $0.17 - $0.35 | $156M | $0.28 | -$0.02 | 1.49M | 579M |
Northwest Biotherapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Jun-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 148,340 | 157,162 | 100,252 | 73,624 |
| Revenue | 1,373 | 412 | 336 | 623 |
| EBITDA | (7,949) | (24,632) | (67,159) | (76,207) |
| Net Income | (13,799) | (35,794) | (73,143) | (80,214) |
| Total Assets | 14,704 | 24,667 | 48,907 | 52,906 |
| Total Debt | 21,126 | 16,797 | 31,429 | 31,711 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Northwest Biotherapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Northwest Biotherapeutics‘s full profile, request access.
Request full access to PitchBookNorthwest Biotherapeutics Competitors (41)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | Corporate Backed or Acquired | Boston, MA | 0 | 00.000 | 000000000 | 00.000 |
| 0000000 | Formerly PE-Backed | Beijing, China | 0000 | 00.000 | 00000000 | 00.000 |
| 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 0000000000. | |
| 000 000000000000 | Venture Capital-Backed | Epalinges, Switzerland | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Venture Capital-Backed | Weston, FL | 000.00 | 000000 - 000 | 000.00 |
Northwest Biotherapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 | 01-Jan-2008 | 000000000000000000 | Biotechnology |
Northwest Biotherapeutics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Northwest Biotherapeutics‘s full profile, request access.
Request full access to PitchBookNorthwest Biotherapeutics Executive Team (7)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Marnix Bosch Ph.D | Chief Technology Officer | ||
| Alton Boynton Ph.D | Chief Scientific Officer & Founder | ||
| Linda Powers JD | Chief Executive Officer & Chief Financial Officer |
4 Former Executives
You’re viewing 3 of 7 executives. Get the full list »Northwest Biotherapeutics Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 00000 0000000000 | Northwest Biotherapeutics | Board Member | 000 0000 | |
| 0000000 000000000 | Self | Director | 000 0000 |
3 Former Board Members
You’re viewing 2 of 5 board members. Get the full list »